What We’re Reading, July 15, 2016: What can the 7 remaining co-ops do to survive; CMS projects increased Medicare spending per enrollee by 2025; and experts call for policy changes to support the health of prisoners at high risk for HIV.
With the rapid failure of the health insurance co-ops—with 4 more announcing there are shutting doors in just the past 2 weeks—only 7 of the initial 23 will still be operational when enrollment begins in fall of this year. Survival will be the bottom line for the remaining consumer operated and oriented plans, as they are called under the Affordable Care Act, since all of them posted losses in 2015, according to Kaiser Health News. According to Timothy Jost, a law professor at Washington and Lee University in Virginia, co-ops are an important alternative to commercial insurers.
According to the CMS Office of the Actuary, the government will be spending over $10,000 a person. The study, which was published in Health Affairs, says healthcare spending will be 20% of the economy by 2025. With 1 in 5 Americans on Medicare, CMS will spend nearly $18,000 annually per member. The lead author on the study, Sean P. Keehan, an economist at the actuary’s office at CMS, told The New York Times that a significant amount of this spending would be the result of high drug prices and greater use of specialty medications.
A series of articles published in The Lancet by experts from the infectious disease field are appealing for policy changes to improve access to treatment, prevention, and care of prisoners post release—especially for those prisoners who are at a high risk of HIV infections. The articles propose solutions such as harm-reduction and drug treatment programs to reduce disease transmission.
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
PAH Treatment Benefits Extend to Patients With Repaired Congenital Heart Disease
March 14th 2025Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ranges from 4% to 28%, according to studies from the US and Europe—and that the prevalence of these comorbid condition is on the rise.
Read More
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More